Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 767-771

  Morse, Gene D ^a,b   Fischl, Margaret A ^c   Shelton, Mark J ^a   Borin, Marie T ^d   Driver, Mary R ^d   DeRemer, Mary ^a   Lee, Kelly ^a   Wajszczuk, Charles P ^d  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEVIRDINE; CD4 ANTIGEN; DIDANOSINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

EID: 0030030556     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.767     Document Type: Article

References (33)

1. Blum, R. A., D. T. D'Andrea, B. M. Florentino, J. H. Wilton, D. M. Hilligoss, M. J. Gardner, E. B. Henry, H. Goldstein, and J. J. Schentag. 1991. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann. Intern. Med 114:754-755.
2. Borin, M. T., A. A. Della-Colletta, and D. H. Batts. 1994. Effects of food and antacid on bioavailability of atevirdine mesylate in HIV+ patients. Clin. Pharmacol. Ther. 55:194. (Abstract.)
3. Bristol-Myers Squibb. 1993. Videx package insert. Bristol-Myers Squibb, Princeton, N.J.
4. Caliendo, A. M., and M. S. Hirsch. 1994. Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect. Dis 18:516-524.
5. Campbell, T. B., K. K. Young, J. J. Eron, R. T. D'Aquila, W. C. Tarpley, and D. R. Kuritzkes. 1993. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201-E) in combination with zidovudine or didanosine. J. Infect. Dis. 168:318-326
6. Cox, S. R., D. H. Batts, A. J. Dietz, C. K. Hanover, B. G. Peel, G. L. Elfring, and B. A. Staten. 1992 A phase I multiple dose study of U-87201E. a non-nucleoside RT inhibitor in normal healthy males, abstr. FOB 3032, p B.92. In Abstracts of the VIII International Conference on AIDS.
7. DeClercq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:119-134.
8. DeRemer, M., R. D'Ambrosio, and G. D. Morse. Didanosine measurement by radioimmunoassay. Submitted for publication.
9. Dueweke, T. J., F. J. Kezdy, G. A. Waszak, M. R. Deibel, and W. G. Tarpley. 1992. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 267:27-30.
10. Dueweke, T. J., S. M. Poppe, D. L. Romero, S. M. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reeusser, M. Busso, L. Resnick, D. L. Mayers, J. Lane, P. A. Aristoff, R. C. Thomas, and W. G. Tarpley. 1993 U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 37:1127-1131.
11. Emini, E. A., W. A. Schleif, V. V. Sardana, C. L. Schneider, J. A. Waterbury. V. W. Byrnes, S. Staszewski, and K. Bakshi. 1993. Combination therapy with AZT prevents selection of HIV-1 variants that are highly resistant to the nonnucleoside reverse transcriptase inhibitor L 697,661, p. 41. In Abstracts of the HIV Drug Resistance Second International Workshop. Professional Postgraduate Services Europe LTD, West Sussex, United Kingdom
12. Fischl, M. A. 1994. Tieatment of HIV infection, p. 141-160. In M. A Sande and P. A. Volberding (ed.), The medical management of AIDS, 4th ed. The W. B. Saunders Co., Philadelphia.
13. Goldman, M. E., J. H. Nunberg, J. A. O'Brien, J. C. Quintero, W. A. Schleif. K. F. Freund, S. L. Gaul, W. S. Saari, J. S. Wai, J. M. Hoffman, P. S. Anderson, D. J. Hupe, E. A. Emini, and A. M. Stern. 1991. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl Acad Sci. USA 88: 6863-6867.
14. Howard, G. M., and F. J. Schwende. 1993. The development of HPLC-based analytical methods for atevirdine, a novel reverse transcriptase inhibitor for the treatment of AIDS, and associated problems with chromatographic performance, abstr. MP-E12. In Abstracts of the 4th International Symposium on Pharmaceutical and Biomedical Analysis, Baltimore.
15. Knapp, M. J., R. R. Berardi, J. B. Dressman, J. M. Rider, and P. L. Carver. 1991. Modification of gastric pH with oral glutamic acid hydrochloride. Clin Pharm. 10:866-869.
16. Lake-Bakaar, G., E. Quadros, S. Beidas, M. Elsakr, W. Tom, D. E. Wilson, H. P. Dincsoy, P. Cohen, and E. W. Straus. 1988. Gastric secretory failure in patients with the acquired immunodeficiency syndrome Ann. Intern Med. 109:502-504.
17. Lelawongs, P., J. A. Barone, J. L. Colaizzi, A. T. M. Hsuan, W. Mechlinski. R. Legendre, and J. Guarnieri. 1988. Effect of food and gastric acidity on absorption of orally administered ketoconazole Clin. Pharm. 7:228-235
18. Mellors, J. W., G. J. Im, E. Tramontano, S. R. Winkler, D. J. Medina, G. E. Dutschman, Z. B. Hengameh, P. Giovanna, C. J. Gonzalez, and Y. C. Cheng. 1993 A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1-jk][1. 4] benzodiazepin-2(1H)-thione(TIBO R82150). Mol. Pharmacol. 43:11-16.
19. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C.-K. Shin, K. Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990 Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250: 1411-1413
20. Metropolitan Life Insurance Co. 1983 1979 Build Study, Society of Actuaries and Association of Life Insurance Medical Directors of America, 1980
21. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
22. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. A. C. Janssen, E. DeClercq, and P. A. J. Janssen. 1990. Potent and selective inhibition of HTV-1 replication in vitro by a novel series of TIBO derivatives. Nature (London) 343:470-474
23. Piscitelli, S. C., T. F. Goss, J. H. Wilton, A. T. D'Andrea, H. Goldstein, and J. J. Schentag. 1991. Effects of ranitidinc and sucralfate on ketoconazole bioavailability. Antimicrob. Agents Chemother 35:1765-1771.
24. Richman, D., and the ACTG 164/168 Study Team. 1993. Nevirapine resistance during clinical trials, p. 26 in HIV Drug Resistance Second International Workshop Professional Postgraduate Services Europe LTD, West Sussex, United Kingdom.
25. Richman, D., A. S. Rosenthal, M. Skoog, R. J. Eckner, T.-C. Chou, J. P. Sabo, and V. J. Merluzzi. 1991. B1-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35:305-308
26. Richman, D., C.-K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffen. 1991 Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245
27. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficicncy virus to antiretroviral agents. Antimicrob. Agents Chemother. 37: 1207-1213.
28. Romero, D. L., M. Busso, C. K. Tan, F. Reusser, J. R. Palmer, S. M. Poppe, P. A. Aristoff, K. M. Downey, A. G. So, L. Resnick, and W. G. Tarpley. 1991. Nonnucleoside reverse transcriptase inhibitors that potentially and specifically block human immunodeficiency virus type I replication. Proc. Natl. Acad. Sci. USA 88:8806-8810.
29. Rosser, L., A. M. O'Donnell, M. DeKemer, and G. D. Morse. 1994. Protein binding characteristics of atevirdine. Antiviral Res. 25:193-200.
30. Saag, M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, K. W. Anderson, F. E. Massari, G. M. Shaw, and the L697,661 Working Group. 1993. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
31. Shelton, M. J., R. G. Hewitt, and G. D. Morse. 1995. Gastric hypoacidity among HIV-infected patients, abstr 495, p. 146. In Abstracts Second National HIV Conference. American Society for Microbiology. Washington, D.C.
32. Shelton, M. J., A. M. O'Donnell, and G. D. Morse. 1992. Didanosine. Ann. Pharmacother. 26:660-670.
33. Vasudevachari, M. B., C. Battista, H. C. Lane, M. C. Psallisopoulos, B. Zhao, J. Cook, J. R. Palmer, D. L. Romero, W. G. Tarpley, and N. P. Salzman. 1992. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology 190:269-277.